Sun Pharma’s Halol Plant Gets FDA ‘OAI’ Status, Hits US Exports

Sun Pharmaceutical Industries has faced a regulatory setback after the U.S. FDA classified its Halol facility as ‘Official Action Indicated’ (OAI) following an inspection (June 2–13), citing CGMP violations. As a result, the plant has been placed on import alert, halting shipments of its products to the U.S. market. The restriction will remain until compliance is restored, though critical medicines may be allowed in case of shortages. Sun Pharma has committed to working with the FDA to address the issues and ensure high-quality standards across its facilities. The alert may impact Sun Pharma’s U.S. revenue in the near term, as the Halol unit is a key manufacturing site. The company’s ability to swiftly rectify the lapses will be crucial in regaining regulatory clearance and maintaining its position in the world’s largest generics market.